Buscopan 10mg 20 pills

1 tab.:

- hyoscine butyl bromide 10 mg

Excipients:

calcium hydrogen phosphate (calcium hydrogen phosphate anhydrous),

dried corn starch,

Hydrolyzed potato starch (soluble starch),

silica colloidal

wine acid,

stearic acid.

Shell composition:

povidone (polyvinylpyrrolidone), sucrose, talc, acacia gum (Arabian gum), titanium dioxide, macrogol 6000 (polyethylene glycol 6000), carnauba wax, white beeswax (white wax).

Farmgroup:

  m-anticholinergic.

Farm action :

 Buscopan is an m-cholinergic blocker.

It has an antispasmodic effect on the smooth muscles of the internal organs, reduces the secretion of digestive glands.

It does not penetrate the BBB (since hyoscine butyl bromide is a Quaternary ammonium derivative), therefore there is no anticholinergic effect on the central nervous system.

- renal colic;
- biliary colic;
- spastic dyskinesia of the biliary tract and gall bladder;
- cholecystitis;
- intestinal colic;
- pylorospasm;
- peptic ulcer of the stomach and duodenum in the acute phase (as part of complex therapy);
- algodismenorea.

The use of the drug Buscopan during pregnancy and during lactation (breastfeeding) is possible only if the intended benefit to the mother outweighs the potential risk to the fetus or infant.

- myasthenia gravis;
- megacolon;
- children's age up to 6 years;
- Hypersensitivity to the components of the drug Buscopan.

Side effect associated with the anticholinergic action of the drug: dry mouth, dry skin, tachycardia; urinary retention is possible (usually mild and resolves on its own).

Allergic reactions: in rare cases, skin manifestations, anaphylaxis with episodes of difficulty breathing.

Buscopan® can enhance the anticholinergic effect of tricyclic antidepressants, antihistamines, quinidine, amantadine, disopyramide, anticholinergics (e.g. tiotropium bromide, ipratropium bromide).

The simultaneous use of Buscopan and dopamine antagonists (for example, metoclopramide) leads to a weakening effect on the gastrointestinal tract of both drugs.

Buscopan® can enhance tachycardia caused by beta-adrenergic agonists.

Adults and children over 6 years of age are prescribed by mouth 1-2 tablets 3-5 times / day.

Tablets should be taken orally with water.

Currently, cases of an overdose of Buscopan® are not described, therefore, the following symptoms and recommendations are theoretical.

Symptoms: anticholinergic effects are possible - urinary retention, dry mouth, redness of the skin, tachycardia, suppression of gastrointestinal motility, transient visual impairment.

Treatment: use of cholinomimetics is indicated. For glaucoma, pilocarpine is prescribed locally (in the form of eye drops).

If necessary, cholinomimetics are prescribed for systemic use (for example, administered in / m or iv neostigmine at a dose of 0.5-2.5 mg); cardiovascular complications are treated according to the usual therapeutic rules; provide supportive and symptomatic therapy; with paralysis of the respiratory muscles - intubation and mechanical ventilation; with urinary retention - catheterization of the bladder.

Use the drug with caution in cases of suspected intestinal obstruction (including pyloric stenosis), with obstruction of the urinary tract (including prostate adenoma), with a tendency to tachyarrhythmias (including atrial fibrillation), angle-closure glaucoma .

The Buscopan tablet contains 41.2 mg of sucrose. The maximum recommended daily dose contains 411.8 mg of sucrose.

Buscopan tablets, coated with a (sugar) white coating, are round, biconvex, with an almost imperceptible smell.